GLP-1 Medications and Parkinson's Disease: What the Research Shows

For more than a decade, neurologists have asked the same question about GLP-1 receptor agonists: if drugs like exenatide and semaglutide can protect neurons in rodent models of Parkinson's disease, could they slow the disease in people?

The answer, after a decade of trials, is now more complicated — and more honest — than the early excitement suggested.

A 2024 New England Journal of Medicine study of lixisenatide reported the first signal that a GLP-1 drug might slow motor progression in early Parkinson's. Less than a year later, the largest and longest GLP-1 trial ever run in Parkinson's disease — the Phase 3 Exenatide-PD3 study published in The Lancet in February 2025 — found no benefit at all.

Here is what the science actually shows about GLP-1 receptor agonists and Parkinson's disease.

Why Researchers Targeted GLP-1 for Parkinson's

Parkinson's disease is driven by progressive loss of dopaminergic neurons in the substantia nigra, accompanied by accumulation of misfolded α-synuclein protein and chronic neuroinflammation. There is no approved treatment that slows the underlying neurodegeneration — current therapies, including levodopa, manage symptoms only.

GLP-1 receptors are expressed throughout the central nervous system, including the substantia nigra. Preclinical work over the past 15 years has identified several mechanisms that made GLP-1 agonists biologically plausible candidates for neuroprotection in Parkinson's:

Dopaminergic neuron survival — GLP-1 signaling activates the PI3K/Akt pathway, which promotes neuronal survival under metabolic and oxidative stress.
Reduced α-synuclein aggregation — Semaglutide reduced α-synuclein pathology and rescued dopaminergic neurons in the MPTP mouse model.
Anti-inflammatory effects on microglia — GLP-1 agonists shift microglia away from pro-inflammatory phenotypes implicated in nigral neurodegeneration.
Mitochondrial function — Improved insulin sensitivity in the brain may correct the bioenergetic deficits seen in Parkinson's neurons.

Evidence: "Semaglutide reduced α-synuclein and showed neuroprotective effects on dopaminergic neurons in the chronic MPTP mouse model of Parkinson's disease, supporting clinical investigation in human disease." — Zhang L, et al. J Parkinsons Dis. 2019. PubMed

These mechanisms are consistent with how GLP-1 drugs appear to act in other parts of the central nervous system — a topic covered in more detail in our piece on GLP-1 medications and brain health.

The mechanistic case was strong. The clinical question was whether it would survive a well-powered randomized trial.

The First Positive Signal: Exenatide-PD (Phase 2, 2017)

The original Phase 2 exenatide trial, published in The Lancet in 2017 by Athauda and colleagues at University College London, randomized 62 people with moderate Parkinson's to exenatide 2 mg once weekly or placebo for 48 weeks, followed by a 12-week washout.

At week 60 — after the medication had been out of the system for 12 weeks — patients on exenatide had MDS-UPDRS Part III off-medication scores that were 3.5 points better than placebo. The persistence of the difference after washout was the headline result: it suggested a disease-modifying effect, not just symptomatic relief.

Evidence: "Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure." — Athauda D, et al. Lancet. 2017;390(10103):1664–1675. DOI: 10.1016/S0140-6736(17)31585-4

This 62-patient trial drove the next decade of investment in GLP-1 trials for Parkinson's. It also set up the central question that the next two trials were designed to answer.

LIXIPARK: Lixisenatide in Early Parkinson's (NEJM, 2024)

The LIXIPARK trial, led by Wassilios Meissner and Olivier Rascol across 21 French centers, randomized 156 people within three years of Parkinson's diagnosis to lixisenatide 20 µg daily or placebo for 12 months, followed by a two-month washout.

At month 12 — while patients were still on treatment — MDS-UPDRS Part III on-medication scores had worsened by 3.04 points in the placebo group but remained essentially unchanged in the lixisenatide group. The between-group difference was statistically significant (p=0.0068).

Evidence: "In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects." — Meissner WG, et al. N Engl J Med. 2024;390(13):1176–1185. DOI: 10.1056/NEJMoa2312323

Two cautions emerged in the same paper:

Patient-reported outcomes were neutral. Patients did not feel that their symptoms had progressed differently between groups. Only the examiner-scored motor exam separated.
Gastrointestinal side effects were common. Nausea affected 46% of the lixisenatide group, and 13% required dose reduction.

The trial design was also limited by a single, relatively short washout period and a Phase 2 sample size of 156. The result was a signal, not a verdict — exactly the kind of finding that demands a properly powered Phase 3 trial.

Exenatide-PD3: The Largest Phase 3 Trial Falls Short

The Exenatide-PD3 trial was designed to be that confirmatory study. Run across six UK centers and led by Thomas Foltynie at University College London, it randomized 194 people with mild to moderate Parkinson's to exenatide 2 mg once weekly or placebo for 96 weeks — the longest GLP-1 trial in Parkinson's to date.

Results were published in The Lancet on February 4, 2025. The trial was negative.

At week 96, MDS-UPDRS Part III off-medication scores had worsened by a mean of 5.7 points in the exenatide group and 4.5 points in the placebo group. The between-group difference favored placebo and was not statistically significant. There were no benefits on patient-reported symptoms, non-motor symptoms, cognition, or quality of life.

Evidence: "Exenatide once weekly did not slow the progression of motor symptoms in people with Parkinson's disease compared with placebo over 96 weeks. These findings do not support the use of exenatide as a disease-modifying treatment for Parkinson's disease." — Vijiaratnam N, et al. Lancet. 2025;405(10477):627–636. DOI: 10.1016/S0140-6736(24)02808-3

Why the discrepancy with the 2017 Phase 2 trial? The likely answers:

The 2017 trial was small (n=62) and the effect size at washout was probably an overestimate driven by chance.
Patient selection differed. Exenatide-PD3 enrolled an earlier, less impaired population, where motor decline over the trial period was slower in both arms.
Exenatide may not cross the blood–brain barrier efficiently. Lixisenatide, which gave a positive Phase 2 signal, has different pharmacokinetic properties.

The result is consistent with a recurring pattern in disease-modifying Parkinson's trials: encouraging Phase 2 signals that fail to replicate in adequately powered Phase 3 studies.

What Trial Comparisons Look Like at a Glance

Trial	Drug	Phase	n	Duration	Primary Outcome
Athauda 2017	Exenatide 2 mg/wk	2	62	60 wks	3.5-point MDS-UPDRS-III benefit at washout
LIXIPARK 2024	Lixisenatide 20 µg/d	2	156	12 mo	No worsening vs. 3.04 pts in placebo (p=0.0068)
Exenatide-PD3 2025	Exenatide 2 mg/wk	3	194	96 wks	No difference; placebo numerically better
MOST-ABLE (ongoing)	Oral semaglutide 14 mg	2	99	Recruited 2023–2024	Pending

The MOST-ABLE trial of oral semaglutide — a drug with potentially better central nervous system penetration than exenatide — is the next clinical readout to watch. Recruitment closed in September 2024 with results expected after the planned data lock in late 2025. Oral semaglutide is the same active ingredient as Rybelsus and is covered in detail in our oral semaglutide for weight loss article.

Real-World Data: Mixed Signals on Parkinson's Prevention

While the disease-modification question remains open, observational data has examined a different question: do people who take GLP-1 drugs for diabetes or obesity have a lower rate of developing Parkinson's in the first place?

A 2025 nationwide Danish cohort study published in the European Journal of Neurology compared GLP-1 receptor agonist users with users of other glucose-lowering drugs. GLP-1 users — the majority on liraglutide — had a modestly lower rate of incident Parkinson's diagnosis over follow-up. The signal was small and the absolute risk reduction was clinically modest, but the direction was consistent with the preclinical hypothesis.

Evidence: "Use of GLP-1 receptor agonists was associated with a reduced rate of incident Parkinson's disease compared with use of other antidiabetic drugs in a nationwide Danish cohort, suggesting a potential neuroprotective effect that warrants further investigation." — Gamborg M, et al. Eur J Neurol. 2025;32(4):e70075. DOI: 10.1111/ene.70075

A 2024 JAMA Network Open study of neurodegeneration outcomes in patients receiving semaglutide or tirzepatide for diabetes and obesity found lower rates of several neurodegeneration endpoints compared with matched controls on other glucose-lowering drugs.

Evidence: "Semaglutide and tirzepatide were associated with reduced risks of several neurodegeneration outcomes compared with other antidiabetic medications in patients with diabetes and obesity." — Wang W, et al. JAMA Netw Open. 2024;7(10):e2436412. DOI: 10.1001/jamanetworkopen.2024.36412

These observational signals are hypothesis-generating, not confirmatory. They cannot distinguish a true neuroprotective effect from confounding by indication: people who tolerate and stay on GLP-1 drugs are systematically different from people who don't, in ways that registries cannot fully adjust for.

What This Means for People with Parkinson's

The current evidence does not support starting a GLP-1 receptor agonist to slow Parkinson's disease.

Exenatide should not be prescribed off-label for disease modification. Phase 3 evidence is clearly negative.
Lixisenatide is not approved for Parkinson's disease and the Phase 2 result has not been replicated.
Oral semaglutide for Parkinson's is still under investigation; the MOST-ABLE Phase 2 readout will inform whether further trials are justified.
Gastrointestinal side effects are common. People with Parkinson's already have a high rate of constipation, gastroparesis, and orthostatic hypotension — all of which can be worsened by GLP-1 drugs.
Weight loss may be unwanted. Many people with Parkinson's lose weight involuntarily as the disease progresses. GLP-1–induced weight loss could compound sarcopenia and frailty.

If you have type 2 diabetes or obesity alongside Parkinson's, the decision to use a GLP-1 drug should be driven by the standard metabolic indications, with side effects monitored carefully. There is no evidence-based reason to choose a GLP-1 drug specifically because of Parkinson's disease at this time.

Key Takeaways

The 2017 Phase 2 exenatide trial generated a decade of optimism that GLP-1 drugs could slow Parkinson's disease.
The 2024 LIXIPARK trial reported a positive Phase 2 signal for lixisenatide on examiner-rated motor scores but not on patient-reported outcomes.
The 2025 Exenatide-PD3 trial — the largest and longest GLP-1 trial in Parkinson's — found no benefit on any measured outcome.
Observational cohort studies suggest a modest reduction in incident Parkinson's diagnoses among GLP-1 users, but these data cannot prove causation.
Oral semaglutide (MOST-ABLE) is the next clinical readout to watch.
GLP-1 drugs are not currently a disease-modifying treatment for Parkinson's disease. Their use should be guided by metabolic indications, with attention to GI side effects and unwanted weight loss.

References

Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675. DOI: 10.1016/S0140-6736(17)31585-4
Meissner WG, Remy P, Giordana C, et al. Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med. 2024;390(13):1176–1185. DOI: 10.1056/NEJMoa2312323
Vijiaratnam N, Girges C, Wretham A, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405(10477):627–636. DOI: 10.1016/S0140-6736(24)02808-3
Zhang L, Zhang L, Li L, Hölscher C. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9(1):157–171. DOI: 10.3233/JPD-181503
Gamborg M, Hvid LG, Thrue C, et al. GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study. Eur J Neurol. 2025;32(4):e70075. DOI: 10.1111/ene.70075
Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. JAMA Netw Open. 2024;7(10):e2436412. DOI: 10.1001/jamanetworkopen.2024.36412
Mulvaney CA, Duarte GS, Handley J, et al. GLP-1 receptor agonists in Parkinson's disease: an updated comprehensive systematic review with meta-analysis. PMC. 2025. PubMed

Last updated: 2026-05-12 Medical review: Dr. James Chen, MD, PhD, FACE